Annexon shares fall as clinical trial results miss expectations

Shares of Annexon Inc. fell on Friday after the biotechnology company reported Phase 2 clinical trial results that did not meet pre-specified primary endpoints.

The company, which focuses on developing treatments for complement-mediated diseases, disclosed that its experimental therapy did not achieve statistically significant improvements compared to placebo in the trial. The announcement triggered a sharp decline in the stock, which was down more than 20% in early trading.

Annexon had previously highlighted the trial as a key catalyst for advancing its lead candidate. The failure to meet endpoints raises questions about the viability of the therapy and the company's broader pipeline strategy. Analysts noted that the setback could delay regulatory submissions and impact investor confidence.

The biotech sector has seen increased scrutiny in recent months, with investors prioritizing data-driven outcomes over speculative pipeline promises. Annexon's stock had surged earlier this year on positive preclinical results, but the latest data has tempered expectations.

The company has not provided additional details on the trial's specifics or next steps, stating only that it is evaluating the full dataset. Investors are likely to await further guidance before reassessing the stock's valuation.

Annexon did not respond to requests for comment.